Prévisions du marché nord-américain du diagnostic du cancer de la peau jusqu’en 2028 – Impact du COVID-19 et analyse régionale par type (mélanome et non-mélanome) et type de dépistage (analyses sanguines, dermatoscopie, tests d’imagerie, biopsie des ganglions lymphatiques et biopsie cutanée)
Le marché nord-américain du diagnostic du cancer de la peau devrait atteindre 2 354,2 millions de dollars américains d\'ici 2028, contre 1 423,0 millions de dollars américains en 2021 ; on estime qu\'il augmentera à un TCAC de 7,5 % entre 2021 et 2028.
Seins, poumons, côlon et rectum , les cancers de la prostate, de la peau et de l\'estomac étaient très courants dans cette région. Selon les données de l’OMS, environ 1,20 million des nouveaux cas signalés en 2020 étaient des cas de cancer de la peau. Le cancer de la peau est de loin le plus répandu de tous les types de cancer. Le mélanome et le non-mélanome sont les deux types de cancer de la peau. Bien que le mélanome représente environ 1 % du total des cas de cancer de la peau, il est à l’origine d’un maximum de décès par cancer de la peau. Le taux d’incidence du mélanome a rapidement augmenté au cours des dernières décennies et varie également avec l’âge. Selon l\'American Cancer Society, le nombre annuel de nouveaux diagnostics de cancer aux États-Unis devrait atteindre environ 99 780 cas en 2022 ; parmi eux, 57 180 patients seraient probablement des hommes et 42 600 seraient des femmes. Il indique en outre que 7 650 personnes devraient mourir à cause du mélanome (5 080 hommes et 2 570 femmes). Selon la Skin Cancer Foundation, entre 2012 et 2022, le diagnostic annuel des cas de mélanome invasif a augmenté de 31 %. Ainsi, l\'incidence du cancer de la peau est susceptible d\'augmenter dans les années à venir, entraînant une demande plus élevée de diagnostics du cancer de la peau.
Avec le nouveau Grâce à leurs fonctionnalités et technologies, les fournisseurs attirent de nouveaux clients et étendent leur présence sur les marchés émergents. Ce facteur stimule la croissance du marché du diagnostic du cancer de la peau à un TCAC prometteur.
Chiffre d’affaires et prévisions du marché nord-américain du diagnostic du cancer de la peau jusqu’en 2028 (millions de dollars américains)
Le marché du diagnostic du cancer de la peau est segmenté en type et type de criblage. En fonction du type, le marché est segmenté en mélanome et non-mélanome. En fonction du type de dépistage, le marché est segmenté en biopsie cutanée, dermatoscopie, biopsie des ganglions lymphatiques, tests d’imagerie et tests sanguins. En fonction des pays, le marché est segmenté entre les États-Unis, le Canada et le Mexique.
SkylineDx BV ; AMLo Biosciences Limitée ; DermLite LLC ; bioMérieux SA ; Veriskin Inc. ; Château Biosciences, Inc. ; DermTech Inc. ; F. Hoffmann-La Roche Ltée; et Michelson Diagnostics Ltd. comptent parmi les principales sociétés sur le marché nord-américain du diagnostic du cancer de la peau.
North America Skin Cancer Diagnostics Strategic Insights
Strategic insights for North America Skin Cancer Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Get more information on this report
North America Skin Cancer Diagnostics Report Scope
North America Skin Cancer Diagnostics Regional Insights
The regional scope of North America Skin Cancer Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
Get more information on this report
Identical Market Reports with other Region/Countries
The List of Companies - North America Skin Cancer Diagnostics Market
SkylineDx BV
AMLo Biosciences Limited
DermLite LLC
F. HOFFMANN-LA ROCHE LTD
bioMerieux SA
Veriskin Inc.
Castle Biosciences, Inc.
DermTech Inc
ACS Dobfar S.p.A
Michelson Diagnostics Ltd.
Frequently Asked Questions
How big is the North America Skin Cancer Diagnostics Market?
The North America Skin Cancer Diagnostics Market is valued at US$ 1,423.0 Million in 2021, it is projected to reach US$ 2,354.2 Million by 2028.
What is the CAGR for North America Skin Cancer Diagnostics Market by (2021 - 2028)?
As per our report North America Skin Cancer Diagnostics Market, the market size is valued at US$ 1,423.0 Million in 2021, projecting it to reach US$ 2,354.2 Million by 2028. This translates to a CAGR of approximately 7.5% during the forecast period.
What segments are covered in this report?
The North America Skin Cancer Diagnostics Market report typically cover these key segments-
Type (mélanome et non-mélanome)
Type de dépistage (analyses sanguines, dermatoscopie, tests d\'imagerie, biopsie des ganglions lymphatiques, biopsie cutanée)
What is the historic period, base year, and forecast period taken for North America Skin Cancer Diagnostics Market?
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Skin Cancer Diagnostics Market report:
Historic Period : 2019-2020
Base Year : 2021
Forecast Period : 2022-2028
Who are the major players in North America Skin Cancer Diagnostics Market?
The North America Skin Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
SkylineDx BV
AMLo Biosciences Limited
DermLite LLC
F. HOFFMANN-LA ROCHE LTD
bioMerieux SA
Veriskin Inc.
Castle Biosciences, Inc.
DermTech Inc
ACS Dobfar S.p.A
Michelson Diagnostics Ltd.
Who should buy this report?
The North America Skin Cancer Diagnostics Market report is valuable for diverse stakeholders, including:
Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.
Essentially, anyone involved in or considering involvement in the North America Skin Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Get Free Sample For North America Skin Cancer Diagnostics Market
1. Complete the form
2. Check your inbox (and spam/junk folder)
3. Your Personal Data is Secure with us
GDPR + CCPA Compliant
Personal & transactional information is kept safe from unauthorized use.
WHAT'S INCLUDED IN FULL REPORT : Market Dynamics,
Competitive Analysis and Assessment, Define Business Strategies, Market Outlook and
Trends, Market Size and Share Analysis, Growth Driving Factors, Future Commercial
Potential, Identify Regional Growth Engines